Trials / Unknown
UnknownNCT04957550
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Psoriatic Arthritis Subjects
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 444 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active psoriatic arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR0302 tablets、Placebo | SHR0302 tablets dose 1 for 48 weeks |
| DRUG | SHR0302 tablets、Placebo | SHR0302 tablets dose 2 for 48 weeks |
| DRUG | Placebo | SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks |
Timeline
- Start date
- 2021-08-30
- Primary completion
- 2024-11-13
- Completion
- 2024-11-13
- First posted
- 2021-07-12
- Last updated
- 2023-02-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04957550. Inclusion in this directory is not an endorsement.